ADDEX THERAPEUTICS LTD (ADXN)

US00654J2069 - ADR

7.79  +0.14 (+1.83%)

Fundamental Rating

3

Taking everything into account, ADXN scores 3 out of 10 in our fundamental rating. ADXN was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of ADXN have multiple concerns. ADXN is valued correctly, but it does not seem to be growing.



Quickly go to:

3

1. Profitability

1.1 Basic Checks

ADXN had positive earnings in the past year.
In the past year ADXN has reported a negative cash flow from operations.
ADXN had negative earnings in each of the past 5 years.
In the past 5 years ADXN always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of 44.42%, ADXN belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
ADXN has a better Return On Equity (48.86%) than 99.11% of its industry peers.
Industry RankSector Rank
ROA 44.42%
ROE 48.86%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin of ADXN (912.38%) is better than 99.47% of its industry peers.
The Operating Margin and Gross Margin are not available for ADXN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 912.38%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

ADXN does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ADXN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ADXN has an Altman-Z score of -34.08. This is a bad value and indicates that ADXN is not financially healthy and even has some risk of bankruptcy.
ADXN has a Altman-Z score of -34.08. This is amonst the worse of the industry: ADXN underperforms 92.21% of its industry peers.
ADXN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ADXN has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.08
ROIC/WACCN/A
WACC4.93%

2.3 Liquidity

ADXN has a Current Ratio of 4.59. This indicates that ADXN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.59, ADXN perfoms like the industry average, outperforming 50.97% of the companies in the same industry.
A Quick Ratio of 4.59 indicates that ADXN has no problem at all paying its short term obligations.
ADXN has a Quick ratio of 4.59. This is comparable to the rest of the industry: ADXN outperforms 52.57% of its industry peers.
Industry RankSector Rank
Current Ratio 4.59
Quick Ratio 4.59

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 119.90% over the past year.
ADXN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -76.09%.
The Revenue for ADXN have been decreasing by -24.47% on average. This is quite bad
EPS 1Y (TTM)119.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.12%
Revenue 1Y (TTM)-76.09%
Revenue growth 3Y-24.84%
Revenue growth 5Y-24.47%
Sales Q2Q%-82.28%

3.2 Future

The Earnings Per Share is expected to grow by 14.71% on average over the next years. This is quite good.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y47.79%
EPS Next 2Y23.07%
EPS Next 3Y16.94%
EPS Next 5Y14.71%
Revenue Next Year-88.67%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 1.51, which indicates a rather cheap valuation of ADXN.
Based on the Price/Earnings ratio, ADXN is valued cheaper than 99.65% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.28, ADXN is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for ADXN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 1.51
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ADXN's earnings are expected to grow with 16.94% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y23.07%
EPS Next 3Y16.94%

More info and screens

0

5. Dividend

5.1 Amount

ADXN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADDEX THERAPEUTICS LTD

NASDAQ:ADXN (1/15/2025, 2:13:01 PM)

7.79

+0.14 (+1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-22 2024-11-22/bmo
Earnings (Next)N/A N/A
Inst Owners3.8%
Inst Owner Change72.84%
Ins Owners10.84%
Ins Owner ChangeN/A
Market Cap8.33M
Analysts38
Price Target8.18 (5.01%)
Short Float %1.57%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.08%
PT rev (3m)-25.07%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-65.92%
Revenue NY rev (3m)-65.92%
Valuation
Industry RankSector Rank
PE 1.51
Fwd PE N/A
P/S 12.89
P/FCF N/A
P/OCF N/A
P/B 0.69
P/tB 0.69
EV/EBITDA N/A
EPS(TTM)5.15
EY66.11%
EPS(NY)-6.75
Fwd EYN/A
FCF(TTM)-6.1
FCFYN/A
OCF(TTM)-6.09
OCFYN/A
SpS0.6
BVpS11.29
TBVpS11.26
PEG (NY)0.03
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 44.42%
ROE 48.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 912.38%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.78%
Cap/Sales 0.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.59
Quick Ratio 4.59
Altman-Z -34.08
F-Score6
WACC4.93%
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)7.14%
Cap/Sales(3y)0.49%
Cap/Sales(5y)0.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)119.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.12%
EPS Next Y47.79%
EPS Next 2Y23.07%
EPS Next 3Y16.94%
EPS Next 5Y14.71%
Revenue 1Y (TTM)-76.09%
Revenue growth 3Y-24.84%
Revenue growth 5Y-24.47%
Sales Q2Q%-82.28%
Revenue Next Year-88.67%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y65.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.22%
EBIT Next 3Y9.49%
EBIT Next 5Y11.54%
FCF growth 1Y63.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.38%
OCF growth 3YN/A
OCF growth 5YN/A